anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ribavirin tablets for a condition for which it was not prescribed. Do not give ribavirin tablets to other people, even if they have the same symptoms that you have.

This Medication Guide summarizes the most important information about ribavirin tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ribavirin tablets that is written for healthcare professionals.
Patients in this expansion cohort will continue study treatment with the MTD until they experience disease progression, unacceptable toxicity or withdraw consent. Patients who discontinue study treatment for reasons other than Progressive-Free Survival (PFS) will continue to have PFS follow-up visits every 2 months for the first 6 months after treatment, and every 3 months until disease progression, death, or start of another anticancer therapy.
Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
INTRODUCTION: Approximately 10-40 million travelers get Traveler's Diarrhea (TD) yearly. A significant decrease in TD incidence has not been achieved by depending solely on antibiotic prophylaxis and educational initiatives. Using prebiotics to prevent TD has also not been examined in previous evaluations of probiotics for TD, which failed to consider the strain-specificity of probiotic efficacy. This review investigates the overall effects of probiotics on preventing TD, including the impact of dosage, duration, and age.
METHODS: Standard literature databases were searched without restriction on publication year or language. The following criteria are included: randomized controlled trials (RCTs) in English or non-English unrestricted to publication year, excluding animal and observational studies. This systematic review applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
RESULTS: Of the 166 screened papers, 10 RCTs were included. Lactobacillus acidophilus showed no efficacy in preventing TD except when mixed with other strains. Other genera of lactobacilli showed a protection rate of up to 39% against TD. Similarly, Saccharomyces cerevisiae and Saccharomyces boulardii have been effective in preventing TD.
CONCLUSION: Studies investigating probiotics as a preventive measure for TD remain limited. Only a few probiotics that reduce TD risk exist. Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD. The effect of additional probiotic strains on TD prevention must be further investigated.
Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD). However, many patients do not receive this treatment due to immune sensitization to HLA antigens. IVIG has been shown to somewhat reduce anti-HLA antibody activity. By blocking this activity, IVIG may make transplants more feasible and increase graft survival in transplant recipients.

Patients are randomized to receive IV infusion of either 2 g/kg (maximum dose 180 g) IVIG 10% S/D (Gamimune-N, 10%, manufactured by Bayer) or placebo (0.1% human albumin, manufactured by Bayer) at time of dialysis at study entry and monthly for 3 months. If patients have not received a transplant at 1 year, they receive a "booster" dose of IVIG or placebo; patients receive another booster at 24 months if transplant still has not occurred. If transplant occurs, patients receive 2 g/kg (up to 180 g) IVIG or placebo monthly for 4 months, beginning at time of transplant. Before and after initiation of IVIG/albumin placebo treatment, specific immune parameters, including panel reactive antibodies (PRA) levels, MLR, serum inhibition of MLR, and cytokine gene transcription in the MLR, and AECA levels are measured. Outcomes studied include time on dialysis and graft survival rates.
PROBLEM TO BE SOLVED: To obtain a food composition and a medicament composition for inhibiting ulcer of digestive organs by including an antiulcer substance having high safety and no side effect as an active principle. SOLUTION: The food composition and the medicament composition include rosemary extract or rosemarinic acid as an active principle. The rosemary extract is prepared by extracting rosemary with a proper solvent. The rosemary is used in a state of the entire plant, its leaf, root bark, stem, root, branch, fruit, seed, flower, or a mixture of two kinds of them. The plant raw material is used in a raw or dried state, and is pref. crushed and then subjected to extraction.
The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
Obesity, a global health challenge, is a major risk factor for multiple life-threatening diseases, including diabetes, fatty liver, and cancer. There is an ongoing need to identify safe and tolerable therapeutics for obesity management. Herein, we show that treatment with artesunate, an artemisinin derivative approved by the FDA for the treatment of severe malaria, effectively reduces body weight and improves metabolic profiles in preclinical models of obesity, including male mice with overnutrition-induced obesity and male cynomolgus macaques with spontaneous obesity, without inducing nausea and malaise. Artesunate promotes weight loss and reduces food intake in obese mice and cynomolgus macaques by increasing circulating levels of Growth Differentiation Factor 15 (GDF15), an appetite-regulating hormone with a brainstem-restricted receptor, the GDNF family receptor α-like (GFRAL). Mechanistically, artesunate induces the expression of GDF15 in multiple organs, especially the liver, in mice through a C/EBP homologous protein (CHOP)-directed integrated stress response. Inhibition of GDF15/GFRAL signalling by genetic ablation of GFRAL or tissue-specific knockdown of GDF15 abrogates the anti-obesity effect of artesunate in mice with diet-induced obesity, suggesting that artesunate controls bodyweight and appetite in a GDF15/GFRAL signalling-dependent manner. These data highlight the therapeutic benefits of artesunate in the treatment of obesity and related comorbidities.
Flubendiamide (FBD) is a novel diamide insecticide extensively used with potential human health hazards. This research aimed to examine the effects of FBD on PrEC prostate epithelial cells, including Oxidative stress, pro-inflammatory responses, modifications in the expression of oncogenic and suppressor miRNAs and their target proteins, disruption of the cell cycle, and apoptosis. Additionally, the research investigated the potential alleviative effect of T-SeNPs, which are selenium nanoparticles biosynthesized by Trichoderma aureoviride, against the toxicity induced by FBD. Selenium nanoparticles were herein synthesized by Trichoderma aureoviride. The major capping metabolites in synthesized T-SeNPs were Isochiapin B and Quercetin 7,3',4'-trimethyl ether. T-SeNPs showed a spherical shape and an average size between 57 and 96.6 nm. FBD exposure (12 μM) for 14 days induced oxidative stress and inflammatory responses via overexpression of NF-κB family members. It also distinctly caused upregulation of miR-221, miR-222, and E2F2, escorted by downregulation of miR-17, miR-20a, and P27kip1. FBD encouraged PrEC cells to halt at the G1/S checkpoint. Apoptotic cells were drastically increased in FBD-treated sets. Treatment of T-SeNPs simultaneously with FBD revealed its antioxidant, anti-inflammatory, and antitumor activities in counteracting FBD-induced toxicity. Our findings shed light on the potential FBD toxicity that may account for the neoplastic transformation of epithelial cells in the prostate and the mitigating activity of eco-friendly synthesized T-SeNPs.
The invention relates to a solid, pharmaceutical composition in compressed tablet form. The tablet comprises an ibuprofen core tablet, a pair of protective barriers and a famotidine outermost coating. The ibuprofen core tablet comprises ibuprofen and one or more pharmaceutically acceptable excipients selected from disintegrants, diluents, fillers, binders, glidants and lubricants. The pair of protective barrier coatings surround the ibuprofen core tablet. The first coating comprises a methacrylic acid and ethyl acrylate copolymer, a surfactant, and hydroxypropylmethylcellulose. The second coating comprises hydroxypropylmethylcellulose, and a plasticizer. The outermost coating comprises famotidine, polyvinyl alcohol and a plasticizer.
PURPOSE:To obtain a production suppresser of anti-idiotype antibody induced by administration with a monoclonal antibody by containing an immunoglobulin as an active ingredient. CONSTITUTION:The objective production suppresser contains an immunoglobulin derived from the animal of species same as the origin of a monoclonal antibody, preferably a non-chemically modified gamma-globulin having a natural state and low anticomplementary value as an active ingredient. As the gamma-globuin, gamma-globulin for intramuscular injection is used and the gamma-globulin agglutinate causing anticomplementary action is preferably removed by using nonionic surfactant, although the gamma-globulin obtained by eliminating the agglutinate with an acid treatment is efficient. The immunoglobulin may be administered simultaneously with a monoclonal antibody or may be individually administrated with the monoclonal antibody. Thereby, side effect in administration of monoclonal antibody is conquered and the monoclonal antibody can be used for prevention or curing of a specific disease (e.g. virus infectious disease, hepatitis B or tumor).
Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut down. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
The Heart of the Family study is a randomized controlled trial conducted to examine if a virtual lifestyle modification intervention is more effective in reducing risk for type 2 diabetes (T2D) and cardiovascular disease (CVD) when it is delivered to family dyads or to individuals and to compare intervention effects in Hispanic and non-Hispanic rural-dwelling adults at-risk for T2D or CVD. The Heart of the Family study will enroll 360 participants - 180 Hispanics and 180 non-Hispanics - from rural communities who have two or more risk factors for T2D or CVD. Participants will be randomized to participate as an individual or with a family member who may or may not be at risk for T2D or CVD or may or may not have diagnosed T2D or CVD for a total of 540 participants. The interventions for both groups will be provided by community health workers using a virtual platform. Both groups will receive eight educational sessions about healthy lifestyle behaviors and support to address personal and environmental barriers to engaging in healthy behaviors. After the eight sessions, the community health workers will follow up with participants once a month by phone over the next 12 months. Primary outcomes include short-term and long-term impact of the family-focused active intervention compared to the individual-focused control condition on type 2 diabetes and CVD biological risk factors (for example, blood pressure and weight) and behavioral risk factors (for example, physical activity and tobacco use). Outcomes are measured at baseline, immediately post-intervention, and at the end of the 12 month period of the study for both groups.
BACKGROUND: Acute heart failure (AHF) is one of the most common cardiovascular diseases. Early diagnosis and prognosis are essential, as they can eventually lead to a fatal condition. Recently, brain natriuretic peptide (BNP) has been recognized as one of the most popular biomarkers for AHF. Changes in glomerular filtration rate (GFR) are often observed in AHF.
METHODS: We searched PubMed, Google Scholar, and ScienceDirect between March and June 2023. Original case control studies written in English that assessed levels oh BNP in AHF were included. Systematic reviews, letters to editor, correspondence, comprehensive reviews, and duplicated studies were excluded. Funnel plots were constructed to assess publication bias.
RESULTS: A total of 9 studies were selected and we obtained the mean difference (MD) of BNP level to be 2.57 (95% CI: 1.35, 3.78), and GFR to be -15.52, (95% CI: -23.35, -7.70) in AHF patients. Sensitivity analyses supported the robustness of the outcome.
CONCLUSION: Results indicated that BNP was a promising prognostic biomarker of AHF, whereas GFR was found to be negatively correlated with AHF.
The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
The present invention relates to a method for capturing a fine material using condensation and relaxation of a biopolymer molecular structure. Specifically, by using a biopolymer in which the condensation degree or relaxation degree of a molecular structure changes according to an environmental change, a fine material comes into contact with a biopolymer in which a molecular structure is relaxed, and the molecular structure of the biopolymer is condensed, such that the fine material is mixed with the biopolymer. When the method for capturing a fine material or a composition for capturing a fine material of the present invention is used, a fine material, specifically, fine dust can be effectively collected. In particular, when skin is applied to a human body, fine dust can be effectively prevented from being deposited to skin, or pre-deposited fine dust can be effectively removed. A collection effect with respect to microorganisms is also excellent, and thus the present invention can also be applied to health hygiene. In addition, when the method for producing a fine material captured structure of the present invention is used, a captured structure having an excellent capturing effect or suitable to be used as an active ingredient of a fine material collecting composition or to apply the fine material collecting method of the present invention can be produced.
The invention relates to a preparation method of a traditional Chinese medicine for treating endometritis, belonging to the technical field of preparation methods of traditional Chinese medicines. At present, endometritis is usually treated with antibiotics, such as ampicillin, but the application of ampicillin can cause discomfort of the gastrointestinal tract, and the intramuscular injection results in pain in parts of the body. Both oral administration and injection can cause allergic response. The traditional Chinese medicine has the technical scheme as follows: immersing honeysuckle, weeping forsythia, neat philippine violet, dandelion, isatis leaf, radix isatidis, herba patriniae, houttuyinia cordata, sargentgloryvine stem, winterchery fruit or calyx, pariphyllin, potentilla discolor, barberry root, sticktight, Japanese cayratia, Japanese raspberry root, coix seed, tuckahoe, rhizoma alismatis, peach kernel, herba leonuri, boneset, red peony root, rhizoma corydalis, nutgrass galingale rhizome, costus root and licorice in 1200 millilitres of water, decocting the mixture with gentle fire, and filtering the decoction to remove slag. The obtained liquid medicine is the traditional Chinese medicine for treating endometritis. The traditional Chinese medicine liquid has the advantages of simple preparation technology, light toxic and side effect of the prepared traditional Chinese medicine liquid, short course of treatment, and high cure rate.
BACKGROUND: Patients with hip-related pain often fail to return to their desired level of activity following hip arthroscopy. Lasting biomechanics alterations may be one potential explanation. Dynamic joint stiffness assesses the mechanistic controls of the lower limb during high impact movements, and thus, may provide valuable clinical targets to improving movement and optimizing return to activity after surgery.
METHODS: Twenty-five participants (13 females) with hip-related pain underwent 3D motion capture during a drop jump task before surgery and six months post-operatively. Nineteen healthy controls (9 females) were collected for comparison. Sagittal plane dynamic joint stiffness was calculated during the initial landing phase. Baseline and 6-month dynamic joint stiffness data were compared 1) between males and females with hip-related pain and 2) between individuals with hip-related pain and controls using Wilcoxon Signed-Rank and Mann Whitney U tests. Sexes were analyzed separately.
FINDINGS: From baseline to 6 months post-operatively, females with hip-related pain demonstrated decreased dynamic ankle stiffness (2.26 Nm/deg. [0.61] to 1.84 Nm/deg. [0.43]) (p = .005) and males with hip-related pain demonstrated increased dynamic hip stiffness (2.73 [0.90] to 3.88 [1.73]) (p = .013). There were no differences in dynamic stiffness at any joint between individuals with hip-related pain at either timepoint when compared to controls (p ≥ .099).
INTERPRETATION: Females and males with hip-related pain may demonstrate unique changes in dynamic joint stiffness after surgery, indicating return to activity may follow different trajectories for each sex. Additional work should examine the relationship between hip joint stiffness and treatment outcomes and identify additional movement-related rehabilitation targets.
BACKGROUND: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents are underway. However, significant concerns exist around the feasibility and safety of offering curative surgery to patients treated within such pathways. The goal in this study was to evaluate the impact of a transition towards a large-scale neoadjuvant therapy program for NSCLC.
METHODS: Medical charts of patients with clinical stage II and III NSCLC who underwent resection from January 2015 to December 2020 were reviewed. The primary outcome was perioperative complication rate between neoadjuvant-treated versus upfront surgery patients. Multivariable logistic regression estimated occurrence of postoperative complications and overall survival was assessed as an exploratory secondary outcome by Kaplan-Meier and Cox-regression analyses.
RESULTS: Of the 428 patients included, 106 (24.8%) received neoadjuvant therapy and 322 (75.2%) upfront surgery. Frequency of minor and major postoperative complications was similar between groups (P = .22). Occurrence in postoperative complication was similar in both cohort (aOR = 1.31, 95% CI 0.73-2.34). Neoadjuvant therapy administration increased from 10% to 45% with a rise in targeted and immuno-therapies over time, accompanied by a reduced rate of preoperative radiation therapy use. 1-, 2-, and 5-year overall survival was higher in neoadjuvant therapy compared to upfront surgery patients (Log-Rank P = .017).
CONCLUSIONS: No significant differences in perioperative outcomes and survival were observed in resectable NSCLC patients treated by neoadjuvant therapy versus upfront surgery. Transition to neoadjuvant therapy among resectable NSCLC patients is safe and feasible from a surgical perspective.
The present invention relates to the process of preparation and use of the urethane dimethyl acrylate monomer of isosorbide (Is-UDMA) in a copolymer formed by two acrylic monomers that are Is-UDMA and Bis-GMA, for obtaining properties with synergistic effect for the development of new dental formulations. The Is-UDMA monomer is prepared in situ, by two synthesis phases and characterized by FTIR spectroscopy and proton nuclear magnetic resonance (+ HRMN) techniques. The dental formulations are prepared from different concentrations were used in weight percentage of the copolymer Is-UDMA / Bis-GMA (0/100) (25/75) (50/50) (75/75) and (100/0) respectively. The efficiency of the Is-UDMA / Bis-GMA copolymer as an organic matrix in the dental formulation is evaluated by conversion of double bonds (DC) by real-time photo-polymerization kinetics (RT-FTIR) by FTIR spectroscopy, viscoelastic properties, shrinkage or contraction and microfiltration in vitro, using premolar teeth. Some combination s achieve making the use of the two acrylic monomers more efficient since they proved to increase the final properties in the evaluated dental resins. Furthermore, in vitro microfiltration tests with dental organs showed that the formulations possess high synergistic potential as dental restorative materials.
A Vitamin A composition comprising an isomeric mixture of an ester of synthetic Vitamin A alcohol consisting essentially of 50 to 60% of the all-trans isomer, 15 to 25% of the 2-cis isomer, 15 to 20% of the 6-cis isomer, and 5 to 10% of the 2,6-di-cis isomer may be made by isomerizing all-trans Vitamin A aldehyde with an acidic material to obtain an isomeric aldehyde mixture corresponding to the above mixture, reducing the aldehyde mixture to the corresponding aldehyde mixture and esterifying the resulting corresponding isomeric aldehyde mixture. The isomeric mixture may also be produced by mixing together the 4 isomers in the proportions stated.  In a preferred process a compound having the formula <FORM:0987061/C2/1> wherein R is an alkyl radical having 1-8 carbon atoms is dehydrated and hydrolysed with hydrochloric acid, chloroform, or carbon tetrachloride as described in Specifications 732,066 and 768,794, reduced to the corresponding alcohols with lithium aluminium hydride, sodium borohydride or potassium borohydride and then esterifying with acetic anhydride or palmitoyl chloride; or with methyl acetate or methyl palmitate in the presence of an alkaline catalyst as described in Specification 816,224.ALSO:A stable Vitamin A composition comprises an isomeric mixture of an ester of synthetic Vitamin A alcohol consisting essentially of 50-60% of the all-trans isomer, 15-25% of the 2-cis isomer, 15-20% of the 6-cis isomer and 5-10% of the 2,6-dis cis isomer. This may be made according to the methods described in Division C2.  A preferred multivitamin aqueous dispersion comprises Vitamin A palmitate isomers of the invention, thiamine mononitrate, riboflavin-5-sodium phosphate, nicotinamide pyridoxine hydrochloride, d-panthenol, ascorbic acid, Vitamin B12.  Vitamin A acetate isomers may also be used, and Vitamin E and K may also be added. Specifications 732,066 and 768,794 are referred to.